Results 161 to 170 of about 288,999 (305)

All‐Flex Plasma Patch for In Vivo Delivery of Reactive Species

open access: yesAdvanced Science, EarlyView.
A fully flexible plasma patch enables stable, conformal treatment on complex biological surfaces and enhances transdermal delivery of reactive species. This platform achieves significant tumor suppression in vivo and reveals coordinated regulation of calcium signaling, metabolism, and programmed cell death, providing a promising strategy for safe and ...
Luxiang Zhao   +8 more
wiley   +1 more source

Endobody: Genetically Encodable Nanobody‐CPP Chimeras for Degradation of Membrane and Extracellular Proteins

open access: yesAdvanced Science, EarlyView.
We introduced genetically encodable, receptor‐independent nanobody‐CPP chimeras, termed endobodies, as robust and modular membrane protein degraders. Additionally, proteasome‐targeting domain (PTD)‐tethered endobody demonstrates further enhanced degradation potency.
Chengjian Zhou   +3 more
wiley   +1 more source

Development and Applications of Chimera Platforms for Tyrosine Phosphorylation. [PDF]

open access: yesACS Cent Sci, 2023
Pergu R   +11 more
europepmc   +1 more source

RBM12 Maintains Glioma Stem Cells by Activating Amino Acid‐Dependent mTORC1 Signaling via SLC7A5 mRNA Stabilization

open access: yesAdvanced Science, EarlyView.
This study shows that in glioma stem cells (GSCs), RBM12 recruits ALKBH5 to remove m6A from SLC7A5 transcripts, thereby enhancing mRNA stability, which elevates large neutral amino acid (LNAA) levels and activates mTORC1, promoting GSC proliferation, self‐renewal, and tumor growth.
Hong Lei   +18 more
wiley   +1 more source

Tyrosine Phosphorylation and Proteolysis [PDF]

open access: yesJournal of Biological Chemistry, 1998
Manuela Vecchi   +4 more
openaire   +1 more source

An Integrative Strategy Delineates Modular Metabolic Remodeling and Potential Therapeutic Targets Across Metabolic Diseases

open access: yesAdvanced Science, EarlyView.
An integrative single‐cell atlas across multiple metabolic diseases reveals coordinated metabolic modules and disease‐shared versus disease‐specific pathway activities. By systematically comparing scoring strategies, a robust RankAve framework is established. Coupled with network analysis and drug‐target prediction, this resource uncovers cross‐disease
Kuan Yang   +10 more
wiley   +1 more source

DHODH Drives Sunitinib Resistance Via a Non‐Enzymatic Mechanism by Inhibiting TRIM28 Ubiquitination and Consequent VEGFA Activation in RCC

open access: yesAdvanced Science, EarlyView.
This non‑enzymatic function of DHODH drives sunitinib resistance by competing with TRIM37 to block TRIM28 ubiquitination, thereby stabilizing TRIM28 and activating VEGFA transcription. Disrupting the DHODH–TRIM28 interaction with lisaftoclax restores drug sensitivity.
Shijie Qian   +10 more
wiley   +1 more source

Targeting the ATX‐LPA Axis Overcomes TKI Resistance and Immunosuppression in Renal Cell Carcinoma via Dual Inhibition of AKT/mTOR and TBK1/IRF3 Pathways

open access: yesAdvanced Science, EarlyView.
ABSTRACT Background Therapeutic resistance limits durable survival in advanced/metastatic renal cell carcinoma (RCC) treated with first‐line tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI). We sought to define key resistance drivers and actionable targets.
Jinchen Luo   +16 more
wiley   +1 more source

Tyrosine phosphorylation coupling of one-carbon metabolism and virulence in an endogenous pathogen. [PDF]

open access: yesProc Natl Acad Sci U S A
Stocke KS   +18 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy